

# Copper (II) Complex of Salicylaldehyde Semicarbazone: Synthesis, Characterization and Antibacterial Activity

## ABSTRACT

Salicylaldehyde semicarbazone ligand and its Cu (II) complex have been synthesized and characterized by a range of physicochemical methods. Experimental data shows the complex is monomeric and the copper atom is four coordinated in a square planar geometry.

The ligand chelates the copper in a tridentate fashion through the carbonyl O, imine N, and phenolato O with the fourth position being occupied by coordinated Cl. Antibacterial activity of the prepared compounds are tested against the microbes *Enterobacter Aerogenes* and *Bacillus Cereus*. The metal complex shows antibacterial activity higher than that of the free ligand.

**Keywords:** Semicarbazone; Tridentate ligand; Complexation; Antibacterial activity

## 1. INTRODUCTION

Semicarbazones are an important class of compounds formed from the condensation of semicarbazide with suitable aldehyde or ketone.

Most of these compounds have a wide spectrum of biological activity including activity against tuberculosis[1] bacterial[2] and viral infections[3], psoriasis[4] and malaria[5]. Salicylaldehyde semicarbazone is obtained by the condensation of “-NH<sub>2</sub>” group of second position to the low electron dense carbonyl carbon and “-C=O” group of salicylaldehyde (Schiff base formation). It is described below in scheme 1.

Metal complexes with potential biological activity are the focus of extensive investigation. Remarkably, complexation with copper improves the biological activity of a wide range of organic

ligands [6, 7]. Copper complex of salicylaldehyde benzoylhydrazone (H<sub>2</sub>sb), [Cu(Hsb)Cl].H<sub>2</sub>O, is an example, which shows tumour inhibitory activity [8]. [Cu(Hsb)Cl].H<sub>2</sub>O was first found to be a potent inhibitor of cell growth and DNA synthesis [9, 10] in a number of human and rodent cell lines [11]. The cytotoxicity of this complex was exposed to exceed many other compounds which were previously known to have such properties, including those used clinically. The Cu(II) complex of the structurally related ligand salicylaldehyde acetylhydrazone (H<sub>2</sub>sa) has also exhibited biological activity [12].

A group of vanadium complexes of salicylaldehyde semicarbazone derivatives were reported for their selective potency on human

46 kidney TK 10 tumour cells[13]. The results  
47 obtained with this study showed that  
48 modification of the semicarbazone backbone  
49 could have a significant effect on the cytotoxicity  
50 of the complexes.

51 The spectral and analytical characterization of  
52 the synthesized complex was carried out to  
53 propose the most probable stereochemistry of  
54 the complex around the Cu(II) ion. In this study,  
55 an antibacterial study has also been involved to  
56 follow the biological potency of the coordination  
57 compound synthesized.

## 58 2. EXPERIMENTAL

59 Semicarbazide (analytical grade),  
60 salicylaldehyde, and copper chloride were used  
61 without further purification.


62 Methanol (GRP), Ethanol (95%),  
63 Dichloromethane (WINLAB GRG 98%) and  
64 DMSO (BDH lab, England 99%) were used as  
65 solvents. Nutrient agar medium (Include-  
66 Peptone, Agar, sugar, marmite) was used to  
67 check anti-microbial activity.

68 Melting points were measured on a digital  
69 melting point apparatus. Elemental analyses for  
70 CHN were performed using a Vario EL cube  
71 [Germany elements (Elemental) analysis

72 system]. FT-IR spectra were recorded on a FT-  
73 IR spectrophotometer [JASCO, FT-IR/4100]  
74 Japan using KBr pellets as the standard  
75 reference. ESI-MS spectra were done with an  
76 Agilent Technologies MSD SL Trap mass  
77 spectrometer with ESI source coupled with an  
78 1100 Series HPLC system. Magnetic  
79 susceptibilities of the metal complexes were  
80 measured using a Sherwood Scientific MX Gouy  
81 magnetic susceptibility apparatus.

### 82 2.1 Synthesis of ligand salicylaldehyde 83 semicarbazone (L)

84 To a stirring solution of *o*-Phenylenediamine  
85 (0.32g, 3 mmol) dissolved in about 20 mL  
86 ethanol, a solution of salicylaldehyde (0.64 mL,  
87 6 mmol) in 10 mL of ethanol was added drop  
88 wise. This has resulted an orange color solution,  
89 which was refluxed for three hours (Scheme 1).  
90 The reaction mixture was cooled and kept for  
91 evaporation at room temperature leading to  
92 isolation of solid orange product. The product  
93 thus formed was filtered and washed several  
94 times with ethanol and dried in oven under  
95 60°C[14, 15]. The product was found to be  
96 soluble in DCM, DMF and DMSO.




**Scheme 1.** Synthesis of ligand salicylaldehyde semicarbazone.

103 **2.2 Synthesis of Copper (II) complex with**  
104 **salicylaldehyde semicarbazone**

105 To the warm ethanolic solution (10 mL) of ligand  
106 L (2 mmol), 10 mL warm ethanolic solution (2  
107 mmol) of Cu(II) chloride was added and the

108 resulting mixture was refluxed for about 3-4  
109 hours. The obtained precipitates were filtered,  
110 washed with ethanol and dried under vacuum on  
111 anhydrous CaCl<sub>2</sub>.

112  
113



114  
115  
116

Fig. 1: Proposed structure of the synthesized complex.

117

118 **2.3 Metal Weight Estimation**

119 A known weight of the metal complex was taken  
120 into a conical flask and concentrated H<sub>2</sub>SO<sub>4</sub>  
121 (500 µL) was added to it. It was fumed down to  
122 dryness and the process was repeated.  
123 Concentrated HNO<sub>3</sub> (500 µL) and HClO<sub>4</sub> (500  
124 µL) were then added and the mixture was fumed  
125 to dryness. The process of adding acids and  
126 fuming down to dryness was continued until  
127 there was no black materials. 100 mL distilled  
128 water was added to dissolve the residue. Finally,  
129 the weight of the metal was estimated  
130 complexometrically [16, 17] using EDTA  
131 (Ethylenediamine tetra acetic acid. Excellent  
132 agreement of results were found.

133 **2.4 Antibacterial Activity Study**

134 Antibacterial activity was checked by the Agar-  
135 ditch method [18]. The *in vitro* antibacterial  
136 screening effects of the examined compounds  
137 were tested against *Bacillus cereus* and  
138 *Enterobacter Aerogenes*. The compounds were

139 dissolved in dimethyl sulfoxide (DMSO) to get  
140 final concentration of 5 mgmL<sup>-1</sup>. In order to  
141 activate the bacterial strain, it was inoculated in  
142 25 mL of Mac Conkey agar and incubated for 24  
143 h at 37<sup>o</sup> C. Activated bacterial strain solution  
144 was prepared in normal saline (0.9% NaCl  
145 solution). The bacterial density was adjusted to  
146 0.5 McFarland standard units. Mueller-Hinton  
147 agar was transferred over sterile 90 mm Petri  
148 dishes. Then 1 mL of activated bacterial strain  
149 solution was inoculated into the media at 40-  
150 45<sup>o</sup> C. The medium was permitted to solidify.  
151 Fine well was made with the help of cork borer  
152 in the plates and  
153 then the plates was filled with test solution  
154 (synthesized compounds dissolved in DMSO  
155 solution). Controls were run for the solvent and  
156 each bacteria. The plates were then incubated  
157 at 37<sup>o</sup> C for 24 h. The inhibition zones produced  
158 by the tested compounds were measured at the  
159 end of the incubation period.

160

161 **3. RESULTS AND DISCUSSIONS**

162 **3.1 Synthesis**

163 The Schiff base ligand, L was prepared in good  
164 yield from the condensation reaction of  
165 salicylaldehyde and semicarbazide in a 1: 1  
166 stoichiometric ratio. Treatment of the Cu(II)

167 chloride salt with the ligand L, formed the  
168 complex corresponding to 1:1 metal-ligand ratio.  
169 Physical and analytical data of studied  
170 compounds are presented in Table 1 and 2.

171

172 **Table 1.** Physical data of the ligand, L and its metal complex.

173

Compound	Empirical Formula	FW (g/mol)	Colour (%yield)	m.p. ( <sup>o</sup> C)
L	C <sub>8</sub> H <sub>9</sub> N <sub>3</sub> O <sub>2</sub>	179.18	White (83%)	218
ClCuL	C <sub>8</sub> H <sub>8</sub> ClCuN <sub>3</sub> O <sub>2</sub>	277.17	Brown (78%)	265

174

175 **Table 2.** Analytical data of the compounds.

176

Compound	Found (Calculated) (%)				$\mu_{\text{eff}}$ (B.M.)	Conductivity ( $\mu\text{Scm}^{-1}$ )
	Cu	C	H	N		
L	-	53.56 (53.63)	5.10 (5.06)	23.74 (23.45)	-	-
ClCuL	22.64 (22.93)	34.71 (34.67)	2.89 (2.91)	15.06 (15.16)	1.76	8

### 177 3.2 Elemental Analysis

178 The micro analysis data of the synthesized  
179 compounds are given in Table 2. The analytical  
180 data suggest that the complex was  
181 mononuclear. The data also reveal that metal to  
182 ligand ratio for the complex is 1:1. Moreover,  
183 these data also supports the proposed structure  
184 of the ligand and complex.

### 185 3.3 Magnetic Measurements

186 The magnetic moment, 1.76 BM is an additional  
187 evidence for the proposed square planar  
188 geometry of the complex,  $ClCuL$  where the  
189 ligand act as tridentates [19, 20] [21, 22].

### 190 3.4 Molar Conductivity Measurements

191 The molar conductance values of  $10^{-3}$  M solution  
192 of the ligand and metal complex in DMSO are  
193 presented in Table 2. The low molar  
194 conductance value revealed that the metal  
195 complex was non-electrolyte in nature [23].

### 196 3.5 FT-IR Studies

197 FT-IR spectrum of the studied compounds are  
198 shown in Fig. 2-3. IR spectrum of the free ligand,  
199 L was compared with the spectra of the complex  
200 to determine the binding mode of the ligand to  
201 metal in the complexes. Characteristic IR peaks  
202 of the ligand and its metal complex are given in  
203 Table 3. The spectrum of the ligand shows the  
204 IR bands at 3458, 3161 and  $3104\text{ cm}^{-1}$  due to  $\nu$   
205  $as(NH_2)$ ,  $\nu\ s(NH_2)$  stretching and  $\nu\ as(NH)$   
206 vibration of free  $NH_2$  groups respectively. The  
207 spectrum also shows bands at 3284, 1692 and  
208  $1594\text{ cm}^{-1}$  due to  $\nu(Phenolic-OH)$ ,  $\nu(>C=O)$  and  
209  $\nu(>C=N)$  groups respectively. A medium  
210 intensity band in the IR spectrum of the ligand at  
211  $3284\text{ cm}^{-1}$  is assigned to an intramolecular  
212 hydrogen bond  $\nu(O-H)$ . This band is absent in  
213 the spectrum of the complex, indicating that the


214 phenolic-OH group is deprotonated. In complex,  
215 a new peak corresponding to phenolic  $\nu(C-O)$  is  
216 observed at  $1317\text{ cm}^{-1}$ . The position of ligand  
217 band due to  $(>C=N)$ ,  $1594\text{ cm}^{-1}$  and  $(>C=O)$ ,  
218  $1692\text{ cm}^{-1}$  is shifted towards lower side to  $1581$   
219  $\text{cm}^{-1}$ ,  $1687\text{ cm}^{-1}$  respectively, indicating the  
220 coordination through the nitrogen atom of the  
221 imine group and oxygen atoms of the ketonic  
222  $(>C=O)$  and phenolic  $-OH$  groups.[24][25, 26].  
223 The coordination through the azomethine  
224 nitrogen and phenolic oxygen to metal atom  
225 were further supported by the appearance of  
226 additional M-N & M-O vibrations in the region  
227  $740\text{ cm}^{-1}$  and  $548\text{ cm}^{-1}$ , respectively in the IR  
228 spectra of the metal complex.

229 **Table 3.** IR ( $\text{cm}^{-1}$ ) and ESI-MS data of the compounds.

230

Compound	$\nu$ (O-H)	$\nu$ (C=O)	$\nu$ (C=N)	$\nu$ (Cu-N)	$\nu$ (Cu-O)	ESI-MS
L	3284	1692	1594	-	-	179.0759
CuCuL	-	1687	1581	740	548	277.0253

231



232

233

**Fig. 2:** IR spectrum of the ligand, L.




Fig. 3. IR spectrum of the complex, ClCuL.

234  
235  
236


### 3.6 ESI-Mass Spectra

The ESI-Mass spectra of the ligand and complex are presented in Fig. 4. The obtained  $m/z$  values are similar to the formula weight (Table 1 and 3)

241 which further supports the proposed structure of  
242 the synthesized compound.

243

244  
245



246  
247  
248

Fig. 4. ESI-Mass spectra of the (a) L and (b) ClCuL

249

### 250 3.7 Antibacterial Activity

251 The antibacterial activity of the compounds were 265 of cells of organisms or the difference in  
252 investigated against the microorganism *Bacillus* 266 ribosomes of bacterial cell [27]. The reasons of  
253 *Cereus* and *Enterobacter Aerogenes* with the 267 showing higher anti-bacterial activity of the  
254 concentration of 5 mgmL<sup>-1</sup> employing agar ditch 268 complex than that of free ligand can be  
255 method. The zone of inhibition were measured 269 explained on the basis of Overtone's concept  
256 in diameter (mm). The antibacterial activity 270 and Tweedy's chelation model [28]. Polarity of  
257 results are presented in Table 4. The metal 271 metal ion is reduced to a greater extent due to  
258 complex showed anti-bacterial activity over the 272 the overlapping of the ligand orbital and partial  
259 free ligand. The ligand, L exhibited very little 273 sharing of positive charge of metal ion with  
260 activity against both the organisms. The 274 donor atoms of the ligand on chelation [29]. The  
261 complex, ClCuL showed high activity against the 275 lipophilic character of the central metal atom is  
262 microbes *Enterobacter Aerogenes*. The variation 276 also increased upon chelation, which  
263 in the activity of metal complex against tested 277 consequently favors the permeation through the  
264 organisms depends on either the impermeability 278 lipid layer of cell membrane [30].

279

280 **Table 4.** Antibacterial activity of the ligand L and its Cu(II) complex (5 mg mL<sup>-1</sup>).

281

Compound	Diameter of inhibition zone of bacteria (mm)	
	Gram positive	Gram negative
	<i>Bacillus cereus</i>	<i>Enterobacter aerogenes</i>
L	+	+
ClCuL	+++	+++

282

*Control (DMSO): No activity (There was no inhibition zone)*

283

*Note: High activity = +++ (Inhibition zone > 12mm and Sight = + (Inhibition zone = 4-8 mm).*

284






Fig. 5. Statistical representation for antibacterial activity for the ligand (L) and its Cu (II) complex.

#### 4. CONCLUSION

The spectral, elemental analysis, conductivity and magnetic measurements data of the synthesized metal complex of Cu(II) with the tridentate ligand, salicylaldehyde semicarbazone have shown square planar geometry. The metal complex is biological active and exhibit enhanced antibacterial activity compared to free ligand.

The antibacterial activity and chemical properties is dependent on molecular structure of the compound. Hence, substitution at the aromatic ring of the ligand can modify the electronic and steric properties of the resulting complexes, which can enable fine-tuning of chemical and biological properties of the ligands and metal complexes.

It is important to note that numerous salicylaldehyde semicarbazone ligands can be readily synthesized using commercially available

derivatives of semicarbazide and salicylaldehyde. A more systematic investigation of such type of metal complexes could be valuable for different biological applications.

#### COMPETING INTERESTS

Authors have declared that no competing interests exist.

327  
328  
329  
330  
331  
332

333 **REFERENCES**

- 334
- 335 1. Domagk, G., et al., *Über eine neue,*  
336 *gegen Tuberkelbazillen in vitro*  
337 *wirksame Verbindungsklasse.*  
338 *Naturwissenschaften*, 1946. **33**(10): p.  
339 315-315.
- 340 2. Sithambaresan, M. and M.P. Kurup, *2-*  
341 *(3-Ethoxy-2-hydroxybenzylidene)-N-*  
342 *phenylhydrazinecarboxamide.* *Acta*  
343 *Crystallographica Section E: Structure*  
344 *Reports Online*, 2011. **67**(11): p. o2972-  
345 o2972.
- 346 3. Thompson, R., et al., *Effect of*  
347 *heterocyclic and other*  
348 *thiosemicarbazones on vaccinia*  
349 *infection in the mouse.* *The Journal of*  
350 *Immunology*, 1953. **70**(3): p. 229-234.
- 351 4. KAMINSKY, A., P. BUMASCHNY, and  
352 J. FISBEIN, *Conteben (TB1/698) in the*  
353 *treatment of psoriasis.* *Prensa medica*  
354 *argentina*, 1953. **40**(21): p. 1263.
- 355 5. Klayman, D.L., et al., *2-Acetylpyridine*  
356 *thiosemicarbazones. 1. A new class of*  
357 *potential antimalarial agents.* *Journal of*  
358 *medicinal chemistry*, 1979. **22**(7): p.  
359 855-862.
- 360 6. Mohindru, A., J.M. Fisher, and M.  
361 Rabinovitz, *Bathocuproine sulphonate: a*  
362 *tissue culture-compatible indicator of*  
363 *copper-mediated toxicity.* *Nature*, 1983.  
364 **303**(5912): p. 64-65.
- 365 7. Ranford, J.D., P.J. Sadler, and D.A.  
366 Tocher, *Cytotoxicity and antiviral activity*  
367 *of transition-metal salicylato complexes*  
368 *and crystal structure of bis*  
369 *(diisopropylsalicylato)(1, 10-*  
370 *phenanthroline) copper (II).* *Journal of*  
371 *the Chemical Society, Dalton*  
372 *Transactions*, 1993(22): p. 3393-3399.
- 373 8. Chan, S., et al., *Copper (II) complexes*  
374 *of the antitumour-related ligand*  
375 *salicylaldehyde acetylhydrazone (H2L)*  
376 *and the single-crystal X-ray structures of*  
377 *[{Cu (HL) H2O} 2] · 2 (NO3) and [{Cu*  
378 *(HL)(pyridine)(NO3)} 2].* *Inorganica*  
379 *chimica acta*, 1995. **236**(1-2): p. 101-  
380 108.
- 381 9. Johnson, D.K., et al., *Cytotoxic*  
382 *chelators and chelates 1. Inhibition of*  
383 *DNA synthesis in cultured rodent and*  
384 *human cells by aroylhydrazones and by*  
385 *a copper (II) complex of salicylaldehyde*  
386 *benzoyl hydrazone.* *Inorganica Chimica*  
387 *Acta*, 1982. **67**: p. 159-165.
- 388 10. Pickart, L., et al., *Inhibition of the growth*  
389 *of cultured cells and an implanted*  
390 *fibrosarcoma by aroylhydrazone*  
391 *analogs of the Gly-His-Lys-Cu (II)*  
392 *complex.* *Biochemical pharmacology*,  
393 1983. **32**(24): p. 3868-3871.
- 394 11. Aruffo, A.A., et al., *Structural studies of*  
395 *Fe (III) and Cu (II) complexes of*  
396 *salicylaldehyde benzoyl hydrazone, a*  
397 *synthetic chelating agent exhibiting*  
398 *diverse biological properties.* *Inorganica*  
399 *Chimica Acta*, 1982. **67**: p. L25-L27.
- 400 12. Dimmock, J., G. Baker, and W. Taylor,  
401 *Aroylhydrazones. 2. ultraviolet*  
402 *spectroscopy and antimicrobial*  
403 *evaluation of some substituted*  
404 *aroylhydrazones.* *CANADIAN*  
405 *JOURNAL OF PHARMACEUTICAL*  
406 *SCIENCES*, 1972. **7**(4): p. 100-103.
- 407 13. Noblíá, P., et al., *Vanadium (V)*  
408 *complexes with salicylaldehyde*  
409 *semicarbazone derivatives bearing in*  
410 *vitro anti-tumor activity toward kidney*  
411 *tumor cells (TK-10): crystal structure of*  
412 *[VVO2 (5-bromosalicylaldehyde*  
413 *semicarbazone)].* *Journal of inorganic*  
414 *biochemistry*, 2005. **99**(2): p. 443-451.
- 415 14. Afsan, F., et al., *Synthesis, Spectral and*  
416 *Thermal Characterization of Selected*  
417 *Metal Complexes Containing Schiff*  
418 *Base Ligands with Antimicrobial*  
419 *Activities.* *Asian Journal of Chemical*  
420 *Sciences*, 2018: p. 1-19.
- 421 15. Mitu, L. and A. Kriza, *Synthesis and*  
422 *characterization of complexes of Mn (II),*  
423 *Co (II), Ni (II) and Cu (II) with an*  
424 *aroylhydrazone ligand.* *Asian Journal of*  
425 *Chemistry*, 2007. **19**(1): p. 658.

- 426 16. Schwarzenbach, G. and H.A. Flaschka, 468  
427 *Complexometric titrations [by] G.* 469  
428 *Schwarzenbach & H. Flaschka.* 1969, 470  
429 London: Methuen. 471
- 430 17. Asraf, M.A., et al., *Structural Elucidation,* 472  
431 *3D Molecular Modeling and Antibacterial* 473  
432 *Activity of Ni (II), Co (II), Cu (II) and Mn* 474  
433 *(II) Complexes Containing Salophen* 475  
434 *Ligand.* Asian Journal of Applied 476  
435 Chemistry Research, 2019: p. 1-15. 477
- 436 18. Parekh, J., et al., *Synthesis and* 478  
437 *antibacterial activity of some Schiff* 479  
438 *bases derived from 4-aminobenzoic* 480  
439 *acid.* JOURNAL-SERBIAN CHEMICAL 481  
440 SOCIETY, 2005. **70**(10): p. 1155. 482
- 441 19. Tas, E., et al., *The sterically hindered* 483  
442 *salicylaldimine ligands with their copper* 484  
443 *(II) metal complexes: Synthesis,* 485  
444 *spectroscopy, electrochemical and thin-* 486  
445 *layer spectroelectrochemical features.* 487  
446 Polyhedron, 2008. **27**(3): p. 1024-1032. 488
- 447 20. El-Sherif, A.A., *Synthesis, spectroscopic* 489  
448 *characterization and biological activity* 490  
449 *on newly synthesized copper (II) and* 491  
450 *nickel (II) complexes incorporating* 492  
451 *bidentate oxygen–nitrogen hydrazone* 493  
452 *ligands.* Inorganica Chimica Acta, 2009. 494  
453 **362**(14): p. 4991-5000. 495
- 454 21. Ruggiero, C.E., et al., *Synthesis and* 496  
455 *structural and spectroscopic* 497  
456 *characterization of mononuclear copper* 498  
457 *nitrosyl complexes: models for nitric* 499  
458 *oxide adducts of copper proteins and* 500  
459 *copper-exchanged zeolites.* Journal of 501  
460 the American Chemical Society, 1993. 502  
461 **115**(24): p. 11285-11298. 503
- 462 22. Willett, R.D., D. Gatteschi, and O. Kahn, 504  
463 *Magneto-structural correlations in* 505  
464 *exchange coupled systems.* 1985. 506
- 465 23. Geary, W.J., *The use of conductivity* 507  
466 *measurements in organic solvents for* 508  
467 *the characterisation of coordination* 509
- 510  
511  
512  
513  
514
- 510 compounds. Coordination Chemistry 511  
512 Reviews, 1971. **7**(1): p. 81-122. 513
- 514 24. Aranha, P.E., et al., *Synthesis,* 515  
516 *characterization, and spectroscopic* 517  
517 *studies of tetradentate Schiff base* 518  
518 *chromium (III) complexes.* Polyhedron, 519  
519 2007. **26**(7): p. 1373-1382. 520
- 521 25. Abd-Elzaher, M.M., *Spectroscopic* 522  
522 *characterization of some tetradentate* 523  
523 *Schiff bases and their complexes with* 524  
524 *nickel, copper and zinc.* Journal of the 525  
525 Chinese Chemical Society, 2001. **48**(2): 526  
526 p. 153-158. 527
- 528 26. Asraf, M.A., et al., *Homogeneous* 529  
529 *photochemical water oxidation with* 530  
530 *metal salophen complexes in neutral* 531  
531 *media.* Photochemical & Photobiological 532  
532 Sciences, 2019. 533
- 534 27. Mounika, K., A. Pragathi, and C. 535  
535 Gyanakumari, *Synthesis* 536  
536 *characterization and biological activity of* 537  
537 *a Schiff base derived from 3-ethoxy* 538  
538 *salicylaldehyde and 2-amino benzoic* 539  
539 *acid and its transition metal complexes.* 540  
540 Journal of Scientific Research, 2010. 541  
541 **2**(3): p. 513-513. 542
- 543 28. Tweedy, B., *Plant extracts with metal* 544  
544 *ions as potential antimicrobial agents.* 545  
545 Phytopathology, 1964. **55**: p. 910-914. 546
- 547 29. Thangadurai, T.D. and K. Natarajan, 548  
548 *Mixed ligand complexes of ruthenium* 549  
549 *(II) containing  $\alpha$ ,  $\beta$ -unsaturated- $\beta$ -* 550  
550 *ketoamines and their antibacterial* 551  
551 *activity.* Transition Metal Chemistry, 552  
552 2001. **26**(4-5): p. 500-504. 553
- 554 30. Alias, M., H. Kassum, and C. Shakir, 555  
555 *Synthesis, physical characterization and* 556  
556 *biological evaluation of Schiff base M (II)* 557  
557 *complexes.* Journal of the Association of 558  
558 Arab Universities for Basic and Applied 559  
559 Sciences, 2014. **15**(1): p. 28-34. 560